Success Metrics

Clinical Success Rate

50.0%

Based on 2 completed trials

Completion Rate

50%(2/4)

Active Trials

3(38%)

Results Posted

100%(2 trials)

Terminated

2(25%)

Phase Distribution

Ph phase_2

50%

Ph phase_3

13%

Ph phase_1

38%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

3(37.5%)

Phase 2Efficacy & side effects

4(50.0%)

Phase 3Large-scale testing

1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(2)

Terminated(3)

Detailed Status

Terminated2

Recruiting2

Completed2

Active, not recruiting1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 3

Trials by Phase

Phase 13 (37.5%)

Phase 24 (50.0%)

Phase 31 (12.5%)

Trials by Status

terminated225%

recruiting225%

active_not_recruiting113%

completed225%

withdrawn113%

Recent Activity

3 active trials

Showing 5 of 8

completedphase_1

Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer

NCT04487756

active_not_recruitingphase_2

Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

NCT04722575

terminatedphase_1

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

NCT04081688

terminatedphase_2

Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy

NCT04770272

completedphase_1

Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

NCT04975958

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT04487756Phase 1

Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer

Completed

NCT04722575Phase 2

Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

Active Not Recruiting

NCT04081688Phase 1

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

Terminated

NCT04770272Phase 2

Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy

Terminated

NCT04975958Phase 1

Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

Completed

NCT05332561Phase 2

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Recruiting

NCT04996017Phase 3

Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)

Recruiting

NCT04272645Phase 2

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

Withdrawn

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8